Aardvark Therapeutics (NASDAQ:AARD) Price Target Raised to $26.00 at Bank of America

Aardvark Therapeutics (NASDAQ:AARD) had its price objective raised by Bank of America from $22.00 to $26.00 in a report released on Thursday morning, Marketbeat.com reports. They currently have a buy rating on the stock.

Several other equities analysts have also weighed in on AARD. Cantor Fitzgerald assumed coverage on shares of Aardvark Therapeutics in a report on Monday, March 10th. They set an “overweight” rating and a $50.00 target price for the company. Morgan Stanley assumed coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They issued an “overweight” rating and a $29.00 price objective for the company. Finally, Royal Bank of Canada assumed coverage on Aardvark Therapeutics in a research report on Monday, March 10th. They set an “outperform” rating and a $21.00 target price on the stock.

Aardvark Therapeutics Stock Performance

Aardvark Therapeutics stock opened at $8.90 on Thursday. Aardvark Therapeutics has a 52 week low of $8.57 and a 52 week high of $19.58.

Insider Transactions at Aardvark Therapeutics

In other Aardvark Therapeutics news, CEO Tien-Li Lee bought 16,542 shares of the stock in a transaction on Friday, February 14th. The shares were bought at an average price of $16.00 per share, with a total value of $264,672.00. Following the purchase, the chief executive officer now directly owns 1,496,175 shares in the company, valued at $23,938,800. This trade represents a 1.12 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Nelson Sun bought 10,000 shares of Aardvark Therapeutics stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $16.00 per share, with a total value of $160,000.00. Following the completion of the transaction, the chief financial officer now directly owns 99,484 shares of the company’s stock, valued at approximately $1,591,744. The trade was a 11.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.